Cipla Limited has reported total revenue of Rs 7216.03 crores, up by 5.28% (YoY) & net profit of Rs 1291.61 crores, up by 9.88% (YoY) in Q1 FY 2026. CIPLA Q1 result very good in healthcare sector.
Cipla will announce its June quarter earnings on Friday, June 2025. Investors should keep an eye on how U.S. sales are doing, what profit margins are expected to look like, and whether the demand for generic drugs is starting to bounce back. Cipla Limited reported total revenue of Rs 7,019.15 crores, up by 9.45% (YoY) & net profit of Rs 1,214.14 crores, up by 30.3% (YoY) in Q4 FY 2025. Tue, 22 Jul 2025 Cipla Limited has entered into definitive agreements to acquire 20% voting rights in iCaltech Innovations Private Limited. Cipla LTD part of NIFTY50 and good for long term investment journey.
Cipla Limited, a global pharmaceutical company established in 1935, is dedicated to providing affordable medicines to those in need. The company manufactures, develops, and markets a wide range of branded and generic formulations and APIs, covering various therapeutic segments. With a presence in India, South Africa, North America, and other markets, Cipla is expanding its portfolio globally.
Cipla Limited is a global pharmaceutical company focused on responsible and sustainable growth of complex generics and deepening portfolio in home markets of India, South Africa and North America, as well as key regulated and emerging markets. Equity Shares of the Company are listed on Bombay Stock Exchange Limited and National Stock Exchange of India Limited.
Business area of the company
The company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has its wide network of manufacturing, trading and other incidental operations in India and International markets.
Products
- Generics and branded generics
- Specialty
- Consumer health
Overview (Cipla ltd)
Major Pharmaceutical Companies With High R&D Expenditure % In Q4 FY25
A company generally incurs R&D expenses in the process of finding and creating new products or services. The amount of money that drug companies devote to R&D is determined by the amount of revenue they expect to earn from a new drug, the expected cost of developing that drug, and policies that influence the supply of and demand for drugs. The rise in R&D expense across companies during the quarter was due to the ongoing clinical trials towards building a pipeline of new products across small molecules, injectables, complex generics & peptides and biosimilars.
MAJOR PHARMACEUTICAL COMPANIES WITH HIGH RESEARCH & DEVELOPMENT EXPENDITURE IN Q4 FY25
Companies Having High QoQ Increase In Mutual Fund Shareholding In Q3 FY25
Mutual fund holding signifies the percentage of shares that are held by the mutual fund houses in respective companies. Significant increase in shareholding by these mutual fund companies may be indicative of growing optimism for that company and better future prospects. A major change in mutual fund ownership is also a reflective measure of any corporate restructuring that the companies might be undergoing and can be gauged to track the same.
COMPANIES HAVING HIGH QOQ INCREASE IN MUTUAL FUND SHAREHOLDING IN Q3 FY25
Disclaimer: The information provided herein is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. All investment strategies and investments involve risk of loss. Individuals should conduct their own research or consult a financial advisor before making any investment decisions. The author/publisher is not a registered investment advisor and does not accept responsibility for any trading losses incurred based on the information provided. Past performance is not indicative of future results.